MILFORD, Mass.--(BUSINESS WIRE)--
Waters plans to present a detailed analysis of its fourth quarter and
full year 2008 business results in its fourth quarter earnings release
and subsequent conference call scheduled for
Waters' non-GAAP E.P.S. primarily excludes purchased intangibles amortization, restructuring charges and other non-operating one-time charges. Some of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Therefore, no reconciliation to GAAP amounts has been provided. Management excludes these items and related tax effects from its non-GAAP adjusted amounts since management believes that these items are not directly related to ongoing operations, thereby providing investors with information that helps to compare ongoing operating performance.
Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
This release may contain "forward-looking" statements regarding future
results and events, including statements regarding expected financial
results, future growth and customer demand that involve a number of
risks and uncertainties. For this purpose, any statements that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words, "believes", "anticipates",
"plans", "expects", "intends", "appears", "estimates", "projects", and
similar expressions are intended to identify forward-looking statements.
The Company's actual future results may differ significantly from the
results discussed in the forward-looking statements within this release
for a variety of reasons, including and without limitation, the impact
of changes in accounting principles or tax rates including the effect of
recently restructuring certain legal entities, the impact on demand
among the Company's market sectors as a result of current global
economic deterioration and recession, the ability to access capital in
volatile market conditions, fluctuations in capital expenditures by the
Company's customers, in particular large pharmaceutical companies,
regulatory and/or administrative obstacles to the timely completion of
purchase order documentation, introduction of competing products by
other companies, such as improved research-grade mass spectrometers,
and/or higher speed and/or more sensitive liquid chromatographs,
pressures on prices from competitors and/or customers, regulatory
obstacles to new product introductions, lack of acceptance of new
products, other changes in the demands of the Company's healthcare and
pharmaceutical company customers, changes in distribution of the
Company's products, risks associated with lawsuits and other legal
actions particularly involving claims for infringement of patents and
other intellectual property rights, and foreign exchange rate
fluctuations affecting translation of the Company's future non-U.S.
operating results. Such factors and others are discussed more fully in
the section entitled "Risk Factors" of the Company's annual report on
Form 10-K for the year ended
Vice President of Investor Relations